Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of ...

ImmunityBio, Inc. faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, ...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2026 to file lead pla ...

UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBCCULVER CITY, Calif ...

Analysis demonstrates a lower cost per sustained responder and cystectomy avoided with ANKTIVA plus BCG compared to TAR-200 ...

ImmunityBio’s findings showed that ANKTIVA plus BCG generated savings of up to $151,438 per cystectomy avoided over a ...

Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

CALGARY, Alberta, May 22, 2026 (GLOBE NEWSWIRE) — The FIM World Supercross Championship tickets will go on sale today at ...

ImmunityBio (IBRX) has been drawing attention after its lead product candidate Anktiva received FDA approval for use with BCG ...

(IMVT) was up 22.7% in pre-market trading, and ImmunityBio Inc. (IBRX) was up 9.3%.

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's core Anktiva drug.

T-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 ...